U.S. Drugmakers Boost Domestic Investments Amid Potential Tariffs
Published on: Jan. 13, 2026, 6:20 p.m. | Source: Devdiscourse
Amid looming 100% tariffs on imported drugs by the Trump administration, global pharmaceutical companies are significantly increasing U.S. investments. Giants like Pfizer, AstraZeneca, and AbbVie are channeling billions into domestic manufacturing and research to mitigate supply chain risks and secure tariff exemptions, while also promising job creation across the nation.
